inclusion criteria: 1. written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. 2. male or female subject ≥18 years of age. 3. laboratory-confirmed sars-cov-2 infection from a test done in a respiratory tract sample within the last 5 days at screening. 4. diagnosis of community-acquired severe covid-19 within 10 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg \< pao2/fio2 ≤300 mmhg, and/or lung infiltrates \>50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 36 hours prior to start of treatment. 5. subject must receive soc treatment for covid-19.

inclusion criteria: 1. written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. 2. male or female subject ≥18 years of age. 3. laboratory-confirmed sars-cov-2 infection from a test done in a respiratory tract sample within the last 5 days at screening. 4. diagnosis of community-acquired severe covid-19 within 10 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg \< pao2/fio2 ≤300 mmhg, and/or lung infiltrates \>50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 36 hours prior to start of treatment. 5. subject must receive soc treatment for covid-19.

inclusion criteria: written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. male or female subject ≥18 years of age. laboratory-confirmed sars-cov-2 infection from a test done in a respiratory tract sample within the last 5 days at screening. diagnosis of community-acquired severe covid-19 within 10 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg < pao2/fio2 ≤300 mmhg, and/or lung infiltrates >50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 36 hours prior to start of treatment. subject must receive soc treatment for covid-19.

inclusion criteria: written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. male or female subject ≥18 years of age. laboratory-confirmed sars-cov-2 infection from a test done in a respiratory tract sample within the last 5 days at screening. diagnosis of community-acquired severe covid-19 within 10 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg < pao2/fio2 ≤300 mmhg, and/or lung infiltrates >50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 36 hours prior to start of treatment. subject must receive soc treatment for covid-19.

inclusion criteria: 1. written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. 2. male or female subject ≥18 years of age. 3. laboratory-confirmed sars-cov-2 infection from a test done in a respiratory tract sample within the last 5 days at screening. 4. diagnosis of community-acquired severe covid-19 within 10 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg < pao2/fio2 ≤300 mmhg, and/or lung infiltrates >50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 36 hours prior to start of treatment. 5. subject must receive soc treatment for covid-19.

inclusion criteria: 1. written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. 2. male or female subject ≥18 years of age. 3. laboratory-confirmed sars-cov-2 infection from a test done in a respiratory tract sample within the last 5 days at screening. 4. diagnosis of community-acquired severe covid-19 within 10 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg < pao2/fio2 ≤300 mmhg, and/or lung infiltrates >50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 36 hours prior to start of treatment. 5. subject must receive soc treatment for covid-19.

inclusion criteria: 1. written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. 2. male or female subject ≥18 years of age. 3. laboratory-confirmed sars-cov-2 infection. 4. diagnosis of community-acquired severe covid-19 within 5 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one clinical respiratory parameter: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg < pao2/fio2 ≤300 mmhg, lung infiltrates >50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 18 hours prior to start of treatment. 5. subject must receive soc treatment for covid-19.

inclusion criteria: 1. written informed consent obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements. 2. male or female subject ≥18 years of age. 3. laboratory-confirmed sars-cov-2 infection. 4. diagnosis of community-acquired severe covid-19 within 5 days after hospital-admission, with severe defined as: need for non-invasive ventilation (niv), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale). at least one clinical respiratory parameter: dyspnea, respiratory frequency ≥30/min, spo2 ≤93%, 100 mmhg < pao2/fio2 ≤300 mmhg, lung infiltrates >50% within 24 to 48 hours. at least one measurement of c-reactive protein ≥50 mg/l within 18 hours prior to start of treatment. 5. subject must receive soc treatment for covid-19.